IND-SWIFT LTD.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹23.35
- Today's High:
- ₹24.29
- Open Price:
- ₹24.29
- 52W Low:
- ₹6.5
- 52W High:
- ₹14.28
- Prev. Close:
- ₹23.82
- Volume:
- 267723
Company Statistics
- Market Cap.:
- ₹672.18 million
- Book Value:
- -130.068
- Revenue TTM:
- ₹4.11 billion
- Operating Margin TTM:
- 6.14%
- Gross Profit TTM:
- ₹1.88 billion
- Profit Margin:
- 6.34%
- Return on Assets TTM:
- 2.46%
- Return on Equity TTM:
- 0%
Company Profile
IND-SWIFT LTD. had its IPO on under the ticker symbol INDSWFTLTD.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. IND-SWIFT LTD. has a staff strength of 0 employees.
Stock update
Shares of IND-SWIFT LTD. opened at ₹24.29 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹23.35 - ₹24.29, and closed at ₹23.35.
This is a -1.97% slip from the previous day's closing price.
A total volume of 267,723 shares were traded at the close of the day’s session.
In the last one week, shares of IND-SWIFT LTD. have increased by +8.1%.
IND-SWIFT LTD.'s Key Ratios
IND-SWIFT LTD. has a market cap of ₹672.18 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.1388.
In the last 12-months IND-SWIFT LTD.’s revenue was ₹4.11 billion with a gross profit of ₹1.88 billion and an EBITDA of ₹538.87 million. The EBITDA ratio measures IND-SWIFT LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IND-SWIFT LTD.’s operating margin was 6.14% while its return on assets stood at 2.46% with a return of equity of 0%.
In Q1, IND-SWIFT LTD.’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.4%.
IND-SWIFT LTD.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 2.58
- PEG
Its diluted EPS in the last 12-months stands at ₹4.81 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IND-SWIFT LTD.’s profitability.
IND-SWIFT LTD. stock is trading at a EV to sales ratio of 2.6258 and a EV to EBITDA ratio of 21.2447. Its price to sales ratio in the trailing 12-months stood at 0.1388.
IND-SWIFT LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹6.49 billion
- Total Liabilities
- ₹9.36 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
IND-SWIFT LTD. ended 2024 with ₹6.49 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹6.49 billion while shareholder equity stood at ₹-7046988000.00.
IND-SWIFT LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹9.36 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹133.28 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹4.03 billion.
IND-SWIFT LTD.’s total current assets stands at ₹2.73 billion while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹1.05 billion compared to accounts payable of ₹2.35 billion and inventory worth ₹893.48 million.
In 2024, IND-SWIFT LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, IND-SWIFT LTD. paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹23.35
- 52-Week High
- ₹14.28
- 52-Week Low
- ₹6.5
- Analyst Target Price
- ₹
IND-SWIFT LTD. stock is currently trading at ₹23.35 per share. It touched a 52-week high of ₹14.28 and a 52-week low of ₹14.28. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹15.53 and 200-day moving average was ₹10.95 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6716.3% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About IND-SWIFT LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrheal, anti-malarial, anti-depressants, cardiology, diabetology, neurology, and oncology. The company also provides contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.